Through Azilsartan treatment, we found that the enhanced BBB or endothelial monolayer permeability and the downregulated occludin were significantly reversed, indicating a potential protective effect of Azilsartan against BBB disruption induced by hyperglycemia. Here, OCLN is linked to Hyperglycemia.